How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1829 participants.

Also called NCT01519518

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,829 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01519518
Other papers using this trial's data
  • Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial Lancet (London, England), 2014-11-22 DOI, PubMed 25002178

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01519518. Randomized; no masking; primary purpose treatment. Start 2012-02 (registry gives no type); primary completion 2013-12 (actual). Results posted on 2015-04-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention
Acronym
HEAT-PPCI
Condition
Acute ST Elevation Myocardial Infarction
Intervention (Drug)
unfractionated heparin
Intervention (Drug)
Bivalirudin
Lead sponsor
Liverpool Heart and Chest Hospital NHS Foundation Trust (class: other)

Record details

Record id
cardio:ct-nct01519518
Content hash
bf836dd127ac839029d736fc315a88ca0a3e77c1a9de201ee7bdba16b3b51c81